Literatura académica sobre el tema "Reactive vaccination"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Reactive vaccination".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Reactive vaccination"
SUMNER, T., L. BURGIN, J. GLOSTER y S. GUBBINS. "Comparison of pre-emptive and reactive strategies to control an incursion of bluetongue virus serotype 1 to Great Britain by vaccination". Epidemiology and Infection 141, n.º 1 (4 de abril de 2012): 102–14. http://dx.doi.org/10.1017/s0950268812000532.
Texto completoAzman, Andrew S. y Justin Lessler. "Reactive vaccination in the presence of disease hotspots". Proceedings of the Royal Society B: Biological Sciences 282, n.º 1798 (7 de enero de 2015): 20141341. http://dx.doi.org/10.1098/rspb.2014.1341.
Texto completoCalin, Andrei, Nick Goulding y Dereck Brewerton. "Reactive arthropathy following Salmonella vaccination". Arthritis & Rheumatism 30, n.º 10 (octubre de 1987): 1197. http://dx.doi.org/10.1002/art.1780301021.
Texto completoWang, Eric, Alexander A. Cohen, Luis F. Caldera Guzman, Pamela J. Bjorkman y Arup K. Chakraborty. "Nanoparticle geometry, immune memory, and antigen presentation determine the cross-reactive antibody response against sarbecoviruses". Journal of Immunology 210, n.º 1_Supplement (1 de mayo de 2023): 223.01. http://dx.doi.org/10.4049/jimmunol.210.supp.223.01.
Texto completoMado, Hubert, Katarzyna Kubicka-Bączyk y Monika Adamczyk-Sowa. "Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report". Journal of International Medical Research 49, n.º 9 (septiembre de 2021): 030006052110443. http://dx.doi.org/10.1177/03000605211044378.
Texto completoMilne, George, Joel Kelso y Heath Kelly. "Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines". Journal of The Royal Society Interface 7, n.º 45 (15 de septiembre de 2009): 573–86. http://dx.doi.org/10.1098/rsif.2009.0312.
Texto completoHo, Tzu-Chuan, Daniel Hueng-Yuan Shen, Chin-Chuan Chang, Hung-Pin Chan, Kuo-Pin Chuang, Cheng-Hui Yuan, Ciao-Ning Chen, Ming-Hui Yang y Yu-Chang Tyan. "Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination". Vaccines 11, n.º 3 (17 de marzo de 2023): 696. http://dx.doi.org/10.3390/vaccines11030696.
Texto completoFaas, Michel R., Willem A. Mak, Hilde Y. Markus, Ellen M. van der Zwan, Marijke van der Vliet, Johannes G. M. Koeleman y David S. Y. Ong. "Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals". Vaccines 10, n.º 12 (13 de diciembre de 2022): 2132. http://dx.doi.org/10.3390/vaccines10122132.
Texto completoAn, Qi-jun, De-an Qin y Jin-xian Pei. "Reactive arthritis after COVID-19 vaccination". Human Vaccines & Immunotherapeutics 17, n.º 9 (25 de mayo de 2021): 2954–56. http://dx.doi.org/10.1080/21645515.2021.1920274.
Texto completoGor, Shivani, Sung-Hee Kim, Khin Yein, Jessica Michael y Elizabeth Price. "C-Reactive protein rise in rheumatology patients following COVID-19 vaccination". Rheumatology Advances in Practice 7, Supplement_1 (24 de marzo de 2023): i2—i5. http://dx.doi.org/10.1093/rap/rkad005.
Texto completoTesis sobre el tema "Reactive vaccination"
Faucher, Benjamin. "Modélisation de la pandémie de COVID-19 pour reconstruire la dissémination du virus et informer la mise en place d’interventions". Electronic Thesis or Diss., Sorbonne université, 2024. http://www.theses.fr/2024SORUS269.
Texto completoEmerging pathogens pose significant challenges to public health authorities. In the context of the COVID-19 pandemic, the SARS-COV-2 and the variants of concern followed a similar pattern. A new virus emerged in one country, spread globally, and then triggered a rapid surge in cases worldwide. To deal with this situation, it is critical to monitor the epidemic, decipher incomplete and incoherent data, and rapidly design interventions. Mathematical models can help interpret heterogeneous surveillance data and inform the design of interventions. In this thesis, we addressed both aspects. First, we developed a mathematical framework to understand how surveillance and epidemic drivers concur in shaping observations. We retrospectively reconstructed the international spread of the Alpha variant in the Fall of 2020 from sequencing and air travel data. In a second work, we focused on intervention. We proposed an agent-based model to quantify the epidemiological impact of a reactive vaccination strategy targeting workplaces and schools where cases are detected. We tested the effectiveness of this strategy to mitigate a general rise in cases and to limit the spread of a new variant
Prévot, Pierre-Paul. "Rôles de la protéine Iris dans l'accomplissement du repas sanguin de la tique Ixodes ricinus". Doctoral thesis, Universite Libre de Bruxelles, 2007. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210730.
Texto completoLa protéine Iris appartient à la famille des inhibiteurs de sérine protéases et présente une homologie significative avec l’inhibiteur d’élastase de leucocytes. Une analyse in silico a confirmé qu’Iris présentait la structure des serpines, et notamment le RCL (Reactive Center Loop), boucle responsable de l’activité anti-protéasique. Comme attendu (sur base de l’analyse in silico), Iris inhibe de manière spécifique l’activité de plusieurs sérine protéases, et en particulier l’élastase de leucocyte. Ces tests effectués, nous avons essayé de comprendre quel(s) pouvai(en)t être le(s) rôle(s) d’Iris dans l’accomplissement du repas sanguin de la tique, c’est à dire dans la lutte contre les différents systèmes de défenses de l’hôte.
Tout d’abord, des tests ont démontré la capacité d’Iris à inhiber les mécanismes de l’hémostase. Des tests sur du plasma et du sang complet ont montré qu’Iris allonge le temps de fibrinolyse, la voie intrinsèque de la coagulation et l’adhésion plaquettaire. L’utilisation de mutants a également démontré que si les deux premières activités sont dépendantes du RCL, et donc d’un mode de fonctionnement anti-protéolytique, l’adhésion plaquettaire est indépendante de ce système. Ce résultat met en évidence l’existence d’autres sites actifs, isolés par analyse in silico, nommés Receptor Binding Domain (RBD).
Un travail antérieur du laboratoire avait permis d’indiquer la capacité de la protéine recombinante Iris semi-purifiée à inhiber la production de TNF-a, d’IL-6, et d’IL-8 (cytokines pro-inflammatoires) ainsi que l’IFN-g par des PBMCs (Peripherical Blood Mononuclear Cells) humaines. Ces résultats ont été confirmés avec de la protéine purifiée. Des analyses complémentaires ont démontré qu’un mutant d’Iris - dépourvu d’activité anti-protéasique - conserve l’activité pro-inflammatoire. Là encore, ce mécanisme semble impliquer un ou plusieurs RBD. L’utilisation d’anticorps dirigés contre ces zones a permis de déterminer le domaine d’interaction (aa :105-120) impliqué dans cette fonction. D’autre part, une analyse par FACS a permis de démontrer qu’Iris interagit uniquement avec les cellules d’origine monocytaire.
Enfin, nous avons également analysé l’importance d’Iris au cours du repas sanguin de la tique par une approche vaccinale. Les résultats observés indiquent que 30 % des tiques nourries sur des lapins immunisés par la protéine rIris ne survivent pas au repas.
Doctorat en sciences, Spécialisation biologie moléculaire
info:eu-repo/semantics/nonPublished
Hoffman, Riley. "Combining a helminth infection with BM32 vaccination for the treatment of grass pollen allergy". Scholarship @ Claremont, 2019. https://scholarship.claremont.edu/cmc_theses/2081.
Texto completoSAINT, PAUL DOMINIQUE. "Le bcg dans la pratique d'un pediatre de lyon de 1969 a 1986 : etude de la reaction locale apres vaccination par bcg chez 2194 enfants (realisee par piqures multiples a l'aide d'une bague, avec deux souches vaccinales) et verification de l'allergie tuberculinique obtenue". Lyon 1, 1990. http://www.theses.fr/1990LYO1M058.
Texto completoPinheiro, Luis Correia. "Vigilância activa de eventos após vacinação". Master's thesis, Faculdade de Ciências Médicas. Universidade Nova de Lisboa, 2008. http://hdl.handle.net/10362/4843.
Texto completoCampos, Teixeira Círbia Silva 1970. "Vacinação contra HPV-16/18 e detecção de Papillomavirus Humano cérvico-uterino no período de 12 anos de seguimento = Vaccination agaisnt HPV16-18 and detection of human papillomavirus in cervix uteri in 12 years period of follow up". [s.n.], 2015. http://repositorio.unicamp.br/jspui/handle/REPOSIP/312845.
Texto completoDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-28T09:15:40Z (GMT). No. of bitstreams: 1 CamposTeixeira_CirbiaSilva_M.pdf: 1128371 bytes, checksum: f7ee3c8128bb7ec40c81ec62521ca6bf (MD5) Previous issue date: 2015
Resumo: Introdução: O câncer cérvico-uterino é causado pelo HPV e a vacinação contra este vírus poderá alterar a prevalência destes na população. Objetivo: avaliar o impacto da vacinação contra HPV na detecção dos diferentes tipos de HPV no período de 12 anos pós-vacinação. Métodos: Em 2001, 91 mulheres do Centro de Campinas para estudos clínicos com a vacina contra HPV-16/18 da GSK, receberam três doses da `vacina¿ contra HPV ou de placebo (Al[OH]3) de forma randomizada e duplo-cega. Elas foram seguidas e realizaram testes de HPV (SPF-10 LiPA) em amostras cervicais coletadas semestralmente até 2010. Informações epidemiológicas, reprodutivas e comportamentais foram obtidas em 2001, 2005, 2010. Em 2012, este estudo local, as participantes retornaram, atualizaram suas informações e coletaram nova amostra, testada por CLART-HPV2 test. Os resultados disponíveis foram agrupados com total de 1492 testes de HPV. Foi analisada a proporção de mulheres com detecção de HPV, por agrupamento viral, a ocorrência de infecção persistente por seis meses (IP6m) por um mesmo HPV de alto risco (HR-HPV) e a relação com idade, novo parceiro sexual nos últimos 12 meses, uso de contraceptivo hormonal ou de preservativos, tabagismo, tipo de vacinação e o tempo decorrido. A análise estatística foi realizada por momento e evolutiva em 12 anos e comparados com a vacina recebida. A análise utilizou os testes x2, exato de Fisher, Mann-Whitney, GEE (equações de estimativa generalizada) e odds ratio com intervalo de confiança de 95% e p<0.5 para significância estatística. Resultados: Os grupos de mulheres `vacinadas¿ e `placebo¿ não apresentaram diferenças na idade e fatores de risco relacionados à aquisição de HPV. Não foi observada diferença na detecção de HPV por momento de coleta da amostra nos 12 anos, avaliados por vacina recebida (53% se vacina contra HPV vs. 47,4% se placebo, p=0,90). Também não houve diferenças significativas para os agrupamentos de HR-HPV, HR-HPV não-HPV16/18, HPV-16/18 e HPV de baixo risco (LR-HPV). Na análise longitudinal a detecção de DNA-HPV apresentou uma tendência de aumento com o tempo para HR-HPV não-HPV16/18 (p=0,03), e de menor detecção de HPV-16/18 (p=0,05) e LR-HPV (p=0,04). Apenas para os HPV-16/18 esta diminuição esteve associada com a vacinação prévia (p=0,05). O uso regular de contraceptivo hormonal esteve associado com 2,4 vezes mais de detecção de LR-HPV (p=0,03), sem relação com a vacinação. Houve 44 episódios de IP6m de HR-HPV, sendo duas vezes mais frequentes em mulheres tabagistas (p=0,03), mas sem relação com a vacinação. Foi observada uma redução, embora não significativa, de IP6m de HR-HPV nas mulheres vacinadas ao longo do tempo (OR=0,68; 95% CI: 0,36-1,28; p=0,23). Conclusões: Não houve diferença na proporção de mulheres com detecção de HPV de qualquer tipo, HR-HPV não-HPV16/18, HPV-16/18 e LR-HPV em relação à vacinação contra HPV-16/18 ou com placebo, em avaliações repetidas por 12 anos. Nas avaliações longitudinais houve uma tendência de menor detecção de HPV-16/18 e menos casos de IP6m por um mesmo HR-HPV detectados nas mulheres previamente vacinadas contra HPV-16/18
Abstract: Introduction: The cervix cancer is caused by HPV and the vaccination in population base against this virus can change their prevalence. Objective: To assess the impact of HPV vaccination in the detection of different types of HPV in 12-years post-vaccination period. Methods: In 2001, 91 women from Campinas Centre started their participation in clinical trial with HPV-16/18 vaccine (GSK) and received three doses of the HPV vaccine or placebo (Al [OH] 3) in a randomized and double-blinded study. They were followed and performed HPV testing (SPF-10 LiPA) in cervical samples collected every six months, until 2010. Information epidemiologic, reproductive and behavioral was obtained in 2001, 2005 and 2010. In 2012, the participants were invited to return in a local study, when the information were updated and a new cervix sample was collected and tested by CLART-HPV2 test. The available results were gathered with a total of 1492 HPV tests. We analyzed the proportion of women with HPV detection by virus group, the occurrence of 6-month persistent infection (6MPI) by the same high-risk HPV (HR-HPV) and the relationship with age, new sexual partner in the last 12 months, use of hormonal contraception or condoms, smoking, type of vaccination and over 12 years. The statistical analysis was performed by moment of sample collection and longitudinally for 12-year period studied and compared by vaccination performed in 2001. The analysis used the tests chi-square, Fisher's exact, Mann-Whitney, GEE (generalized estimating equations) and odds ratios with 95% confidence interval and p<0.5 for statistical significance. Results: the women from groups 'vaccinated' and 'placebo' did not differ in age and risk factors related to the HPV acquisition. There was no difference in HPV detection by time of sample collection for over 12 years, according to the received vaccine (53% for HPV vaccine vs. 47.4% for placebo, p=0.90). There were also no significant differences for HPV groupments, HR-HPV, HR-HPV non-HPV16/18, HPV-16/18 and low risk HPV (LR-HPV). The longitudinal analysis of DNA-HPV detection showed an increasing trend over time for HR-HPV non-HPV16/18 detection (p=0.03), and a decreasing trend for detection of HPV-16/18 (p=0.05) and LR-HPV (p=0.04). Just for HPV-16/18 the decrease trend was associated with prior HPV vaccination (p=0.05). Regular use of hormonal contraceptive was associated with 2.4 times more LR-HPV detection (p=0.03), but unrelated to vaccination. There were 44 episodes of HR-HPV 6MPI, and their occurred twice more if the women smokes (p=0.03), but unrelated to vaccination. The HR-HPV 6MPI over the 12-year studied had a decreasing pattern in HPV vaccinated women, although not significant (odds ratio=0.68, 95% CI: 0.36 - 1.28; p=0.23). Conclusions: There was no difference in the proportion of women with detection of HPV (any type), HR-HPV non-HPV16/18, HPV-16/18 and LR-HPV in relation to vaccination against HPV-16/18 or placebo in repeated cervix samples for 12 years. In the longitudinal assessments there was a decreasing trend for detecting HPV-16/18 and less episodes of 6MPI of the same HR-HPV in women previously vaccinated against HPV-16/18
Mestrado
Oncologia Ginecológica e Mamária
Mestra em Ciências da Saúde
Denis, Jessica. "Discrimination sérologique de flavivirus, étude du domaine III de la protéine d’enveloppe du virus Zika comme cible d’anticorps spécifiques. High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel. Vector-Borne Transmission of the Zika Virus Asian Genotype in Europe". Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS078.
Texto completoThe Zika virus, like the dengue virus, is a Flavivirus and both are transmitted by Aedes mosquitoes. In 2015, an epidemic caused more than 700,000 infections, leading to foetal microcephaly and Guillain Barré syndrome. In addition, sexual transmission of the Zika virus was demonstrated for the first time. Flaviviruses co-circulate in many countries, sometimes concomitantly. Infections with Flaviviruses induce cross-reacting antibodies, leading to cross-neutralization or, on the contrary, worsening of the disease following a second infection, depending on their concentration and affinity. Such cross-reaction leads to two principle problems: (i) it is difficult to make a reliable serodiagnosis and (ii) a vaccine may aggravate the disease instead of providing protection. Here, we evaluated the reliability of antibodies induced during human infections to recognise envelope protein domain III of the Zika virus. This domain carries epitopes recognized by the IgG produced during a Zika virus infection, making it a specific marker. An ELISA developed to detect this domain shows 92% sensitivity and 90% specificity. We used this tool to diagnose an old case from a pre-epidemic area as well as an indigenous case from the south of France in 2019. Monitoring the kinetics of the appearance and disappearance of IgM and IgG in the blood of patients for one year allowed us to estimate the window of use for our diagnostic tool, while characterizing the humoral immune responses linked to the epidemic and the severity of the disease, as well as the presence of a serological scar. Finally, the study of antibodies induced by this domain complexed to nanoparticles in an animal model showed such nanoparticles to be a strong adjuvant and the antibodies to specifically recognize the Zika virus
Näslund, Jonas. "Rift Valley fever development of diagnostics and vaccines /". Umeå : Department of Clinical Microbiology, Umeå university, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-30676.
Texto completoCouto, Carla Renata. "Viroses respitarórias após vacinação contra influenza em profissionais de saúde (Projeto Tira-teima)". Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-27052010-161855/.
Texto completoINTRODUCTION: Compliance with influenza vaccination has been historically poor among health care workers (HCW), ranging from 2 to 36% world around. The occurrence of respiratory symptoms following influenza vaccination is frequently taken as vaccine failure which reinforces vaccine disbelief. A preliminary study conducted at Hospital das Clínicas, University of São Paulo School of Medical Sciences, showed that the main reasons for non-compliance with influenza vaccination were the perception of vaccine inefficacy and fear of adverse events. OBJECTIVES: To determine the incidence of adverse events after seasonal influenza vaccination and identify other respiratory viruses causing upper respiratory infections in vaccinated HCWs. METHODS: A cohort of 398 vaccinated HCWs was prospectively surveyed for the occurrence of any adverse event in the first 48h after vaccination. A subset of the original cohort (337 HCWs) was followed up during four months, twice a week, for the detection of respiratory symptoms. Nasal washes were taken if respiratory symptoms occurred. Direct immunofluorescent assay (DFA) was performed for the detection of respiratory syncytial virus (RSV), influenza (INF) A and B, parainfluenza (PIV) 1, 2 and 3, and adenovirus (ADV). PCR was performed for the detection of human rhinoviruses (HRV), ADV and coronaviruses (hCoV); and real time PCR for the detection of human metapneumovirus (hMPV). To assure greatest sensitivity of influenza diagnosis, real time PCR was added to the diagnostic tools of influenza viruses. RESULTS: Adverse events were reported by 30% of the HCWs, being headache and myalgia reported by 50% and 47% of the participants, respectively. No severe adverse event was observed. One hundred and twenty-one HCWs (35.9%) developed 192 episodes of respiratory symptoms during follow-up and nasal washes were taken in 93 of them. Influenza A virus was detected in five of the 93 episodes (5.3%) and other respiratory viruses in 26 (27.9%). In the remaining 61 episodes (65.6%) no respiratory virus was identified. The incidence density of influenza was 4.3 episodes per 100 HCW-month, while the incidence density of other respiratory viruses was 10.8 episodes per HCW-month. CONCLUSIONS: Influenza vaccine is safe. The fear of adverse events as well as the perception of vaccine inefficacy seems to be unjustified in this population. The present study showed that the occurrence of upper respiratory infection during the four months following seasonal influenza vaccination of HCWs is generally caused by other respiratory viruses (28%) and not by influenza viruses (5%)
CHANG, YEN-LING y 張燕菱. "The Study on the Factors for Influenza Vaccination Behavior and Reaction of Hospital Employee:Using Health Service Utilization Model". Thesis, 2017. http://ndltd.ncl.edu.tw/handle/ykvd8b.
Texto completo中臺科技大學
醫療暨健康產業管理系碩士班
105
The aim of this study was to investigate the effects of influenza vaccination on health care practitioners with cross-sectional study by applying Andersen’s f-ourth-generation health service utilization model. A total of 301 valid questionn-aires were collected from public hospital nurses, radiologists, pharmacists, med-ical staff and administrative staff in central Taiwan. The major findings were as follows. The domains included in the questionnaire are the following: demogra-phic characteristics, healthy behaviors, health status and health believe to ward influenza vaccination. The data was analyzed by SPSS 18.0, using descriptive s-tatistics, t-test, Chi-square and logistic regression. The results show that, in terms of personal factors, there was no pregnancy (p = 0.001), no history of drug allergy (p <0.001), influenza vaccination is higher than the pregnancy / drug allergy group. In the case of vaccine brand effects (p <.05) and previous influenza vaccination (p <0.001), influenza vaccination rates were higher than those of non-vaccinated groups. In terms of health status, the normal health status (p <.05) and the health status compared with those of the same age (p <.05), indicating that influenza vaccine comparing with poor health is better than healthy people. There was no significant difference in health behavior. From this study, we noticed that the willingness to have influenza vaccinat-ion is associated with pregnant women, diabetes duration, perceived benefits and cues to action. The age of the individual and his/her diabetes duration could not be altered. Therefore this study suggests that medical professionals play a very i-mportant role in influenza prevention and the promoting of influenza vaccinatio-n. Enhancing the doctor-patient relationship and the trust in the medical team w-ill be a very important key. This study suggests that medical professionals should have sufficient and c-orrect knowledge about influenza and its vaccination. Adequate information and health education about influenza vaccination should be provided not only to the patients, but also to their family members. The correct concept could be promo-ted via community activities; TV or radio broadcasts, or even during the waiting time in OPD sessions. Health department of local government should also hold seminar and lectures concerning this topic to disseminate the correct concept. Keywords: Medical professionals, Influenza vaccines, Health service utili-zation model, Vaccination behavior, Side effects
Libros sobre el tema "Reactive vaccination"
Woodroffe, Rosie y Christl A. Donnelly. European badgers and the control of bovine tuberculosis in the United Kingdom. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198759805.003.0020.
Texto completoBridges, Sarah. Bad Reaction: A Memoir. Skyhorse Publishing Company, Incorporated, 2016.
Buscar texto completoBridges, Sarah. Bad Reaction: A Memoir. Skyhorse Publishing Company, Incorporated, 2016.
Buscar texto completoChoi, Eun Kyung y Young-Gyung Paik. ‘A vaccine for the nation’: South Korea’s development of a hepatitis B vaccine and national prevention strategy focused on newborns. Manchester University Press, 2017. http://dx.doi.org/10.7228/manchester/9781526110886.003.0005.
Texto completoShingles. Exon Publications, 2024. http://dx.doi.org/10.36255/shingles.
Texto completoCapítulos de libros sobre el tema "Reactive vaccination"
Novakova, Silviya Mihaylova, Plamena Ivanova Novakova y Maria Toncheva Staevska. "Acute Reaction to Influenza Vaccination". En Pediatric Allergy, 131–34. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18282-3_25.
Texto completoLee, Po-Chang, Shwu-Huey Wu, Yu-Pin Chang y Joyce Tsung-Hsi Wang. "Innovative Applications of the Medical Information". En Digital Health Care in Taiwan, 129–52. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-05160-9_7.
Texto completoOude Elberink, J. N. G. "Is het bij een bestaande anafylactische reactie op een wespensteek zinvol de patiënt bij andere vaccinaties 1 uur onder controle te houden?" En Vademecum permanente nascholing huisartsen, 1640. Houten: Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8808-0_866.
Texto completoMeerwijk, Maurits Bastiaan. "Conclusion". En A History of Plague in Java, 1911-1942, 161–70. Cornell University Press, 2022. http://dx.doi.org/10.7591/cornell/9781501766824.003.0007.
Texto completoAkhter, Naheed, Sadia Sana, Muhammad Adnan Ahsan, Zafaar Siddique, Abu Huraira y Somara Sana. "Advances in Diagnosis and Treatment for SARS-CoV-2 Variants". En Infectious Diseases. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.107846.
Texto completoCrawford, Dorothy H. "9. Turning the tables". En Viruses: A Very Short Introduction, 110–25. Oxford University Press, 2018. http://dx.doi.org/10.1093/actrade/9780198811718.003.0010.
Texto completoHoffmann, Andreas, Claudia Dumke y Kay-Martin Ove Hanschmann. "Thermal Imaging". En Innovative Research in Thermal Imaging for Biology and Medicine, 220–36. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-2072-6.ch010.
Texto completoHaigh, John. "What is probability?" En Taking Chances, 1–12. Oxford University PressOxford, 2003. http://dx.doi.org/10.1093/oso/9780198526636.003.0001.
Texto completoFahmy, Khaled. "Medicine and Public Health in the Nineteenth Century". En The Oxford Handbook of Modern Egyptian History, 9–31. Oxford University Press, 2024. http://dx.doi.org/10.1093/oxfordhb/9780190072742.013.5.
Texto completoAlexander, Graeme J. M. y Kate Nash. "Hepatitis A to E". En Oxford Textbook of Medicine, editado por Jack Satsangi, 3108–19. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0323.
Texto completoActas de conferencias sobre el tema "Reactive vaccination"
Nesbitt, R., AS Azman, VK Asilaza, JK Edwards, P. Nkemenang, P. Gakima, P. Gitahi et al. "Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan". En MSF Scientific Days International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/wm3ci4j.
Texto completoNesbitt, R., J. Rumunu, VK Asilaza, P. Gitahi, P. Nkemenang, M. Haile, J. Duncker et al. "Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against hepatitis E in Bentiu, South Sudan". En MSF Scientific Days International 2023. NYC: MSF-USA, 2023. http://dx.doi.org/10.57740/qdmj-8n51.
Texto completoMamaty, AA, S. Atti, KA Sani, G. Tonamou, I. Ciglenecki, K. Chamman, AW Kitembo et al. "Measles seroprevalence after repeated epidemics and reactive vaccination campaigns in Magaria and Mirriah, Niger in 2023". En MSF Scientific Days International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/qlihoz.
Texto completoNesbitt, RC, J. Rumunu, VK Asilaza, P. Gitahi, P. Nkemenang, M. Haile, J. Duncker et al. "Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan". En MSF Scientific Day International 2023. NYC: MSF-USA, 2023. http://dx.doi.org/10.57740/0zh3-kk31.
Texto completoAsilaza, VK. "Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan". En MSF Scientific Day International 2023. NYC: MSF-USA, 2023. http://dx.doi.org/10.57740/sej1-ar65.
Texto completoBeronja, Branko, Olja Stevanović, Nataša Nikolić, Nevena Todorović, Ana Filipović, Jelena Simić, Tatjana Gazibara, Jelena Dotlić y Ivana Milošević. "Gender-specific mortality predictors in patients with severe COVID-19: A critical care perspective". En Proceedings of the International Congress Public Health - Achievements and Challenges, 81. Institute of Public Health of Serbia "Dr Milan Jovanović Batut", 2024. http://dx.doi.org/10.5937/batutphco24036b.
Texto completoGignoux, EM. "Safety of hepatitis E vaccine in pregnancy emulating a target trial following a mass reactive vaccination campaign in South Sudan". En MSF Scientific Day International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/ljs5xz.
Texto completoGignoux, EM. "Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan". En MSF Scientific Day International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/wcoyoa.
Texto completoNesbitt, R., AS Azman, VK Asilaza, JK Edwards, P. Nkemenang, P. Gakima, P. Gitahi et al. "Safety of hepatitis E vaccine in pregnancy emulating a target trial following a mass reactive vaccination campaign in South Sudan". En MSF Scientific Days International 2024. NYC: MSF-USA, 2024. http://dx.doi.org/10.57740/tmxctziln.
Texto completoRagulskaya, M. y E. Tekutskaya. "Solar-terrestrial relations: solar activity and the COVID-19 pandemic". En ASTRONOMY AT THE EPOCH OF MULTIMESSENGER STUDIES. Proceedings of the VAK-2021 conference, Aug 23–28, 2021. Crossref, 2022. http://dx.doi.org/10.51194/vak2021.2022.1.1.130.
Texto completoInformes sobre el tema "Reactive vaccination"
Gershoni, Jonathan M., David E. Swayne, Tal Pupko, Shimon Perk, Alexander Panshin, Avishai Lublin y Natalia Golander. Discovery and reconstitution of cross-reactive vaccine targets for H5 and H9 avian influenza. United States Department of Agriculture, enero de 2015. http://dx.doi.org/10.32747/2015.7699854.bard.
Texto completoPerk, Simon, Egbert Mundt, Alexander Panshin, Irit Davidson, Irina Shkoda, Ameera AlTori y Maricarmen Garcia. Characterization and Control Strategies of Low Pathogenic Avian Influenza Virus H9N2. United States Department of Agriculture, noviembre de 2012. http://dx.doi.org/10.32747/2012.7697117.bard.
Texto completoDing, Yukang, Xixia Chen y Yongpeng Ge. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septiembre de 2022. http://dx.doi.org/10.37766/inplasy2022.9.0084.
Texto completoBercovier, Herve, Raul Barletta y Shlomo Sela. Characterization and Immunogenicity of Mycobacterium paratuberculosis Secreted and Cellular Proteins. United States Department of Agriculture, enero de 1996. http://dx.doi.org/10.32747/1996.7573078.bard.
Texto completoKnowles, Donald y Monica Leszkowicz Mazuz. Transfected Babesia bovis expressing the anti-tick Bm86 antigen as a vaccine to limit tick infestation and protect against virulent challenge. United States Department of Agriculture, enero de 2014. http://dx.doi.org/10.32747/2014.7598160.bard.
Texto completoGelb, Jr., Jack, Yoram Weisman, Brian Ladman y Rosie Meir. Identification of Avian Infectious Brochitis Virus Variant Serotypes and Subtypes by PCR Product Cycle Sequencing for the Rational Selection of Effective Vaccines. United States Department of Agriculture, diciembre de 2003. http://dx.doi.org/10.32747/2003.7586470.bard.
Texto completo